Panbela Therapeutics, Inc. Common Stock
PBLA
PBLA was delisted on the 6th of March, 2024.
5 hedge funds and large institutions have $71.8K invested in Panbela Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
12.59% less ownership
Funds ownership: 14.52% → 1.93% (-13%)
17% less funds holding
Funds holding: 6 → 5 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
92% less capital invested
Capital invested by funds: $945K → $71.8K (-$873K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$60.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.89K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$34 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$542K |
| 2 |
Walleye Capital
New York
|
-$217K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$175K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.89K |
PBLA Hedge Fund Activity: Q3 2023 in Review
5 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q3 2023, worth a combined $71.8K — down 92% from $945K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PBLA and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $60.2K. The largest seller was Sabby Management, exiting entirely with an estimated $542K sold.
- 5 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q3 2023, down from 6 in Q2 2023.
- Funds reported $71.8K of Panbela Therapeutics, Inc. Common Stock stock for Q3 2023, down 92% quarter-over-quarter.
- 3 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Panbela Therapeutics, Inc. Common Stock buyer in Q3 2023 was Citadel Advisors, an estimated $60.2K added.
- The largest Panbela Therapeutics, Inc. Common Stock seller in Q3 2023 was Sabby Management, an estimated $542K sold.
Based on aggregated 13F filings for Q3 2023.